A team of investigators conducted a phase 3, multicenter study with a double-blind, randomized withdrawal period to assess the effects of twice-daily osilodrostat in patients with Cushing disease.
Several research studies presented at ENDO 2021 have evaluated the molecular mechanisms underlying Cushing syndrome to facilitate earlier diagnosis and improve disease management.
Osilodrostat treatment was found to be associated with a rapid and sustained reduction in mean concentration of urinary free cortisol and improved clinical symptoms in patients with Cushing’s disease.
Patients with Cushing syndrome are at an increased risk for infections, including severe COVID-19, due to immunodeficiency and other comorbidities.
Isturisa is exclusively available through the R.A.R.E.™ Patient Support Program and distributed via AnovoRx specialty pharmacy.
The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.
No reference criteria can definitively distinguish patients with primary aldosteronism and subclinical Cushing syndrome from those with these conditions alone.
The clinical approach to management of Cushing disease is often complex and education on a clear approach is paramount.
According to results of the phase 3 SONICS trial, levoketoconazole is a safe and effective treatment option for patients with Cushing syndrome.
Researchers examined sex differences in clinical presentation and patient outcomes in ACTH-dependent Cushing syndrome.
